PAST OR ABSENT Board members of the lsinj


PAST BOARD MEMBERS OF THE LSINJ - ON SABBATICAL OR NEW AFFILIATION RESTRICTIONS OR GRADUATED STUDENTS OR INACTIVE

Adam Bogart, Ph.D.

Position and Role in LSINJ: Chief of Imaging Operations (CIO); Chief of Statistical and Mathematical Operations (CISMO)

Interests: Neuropsychiatric diseases, neuroimaging and MRI modeling of neuropsychiatric diseases; Neurodegeneration and Aging. Radiology and statistical analysis of brain metabolites during normal aging and pathological animal models of Neurodegenerative Disease under conditions of caloric restriction.

Member of Working Group in LSINJ and Group Leader: Neurosciences, Neuropsychiatry, Neurophysiology and Psychology, Thermodynamics of Neural Functions under Hypoxic Conditions, Stroke and Ischemia in Anoxia Tolerant Turtle brains, Mutational Basis of Brain Cancers and Neurodegenerative Diseases - George Perry, Ph.D., Adam Bogart, Ph.D., Ralph Sherman, B.S., Alex Diaz, Ph.D., & Ferez Nallaseth, Ph.D. & Sina Varmaghani, M.Sc.(Group Leader – George Perry, Ph.D.); Neuropsychiatric diseases, neuroimaging and MRI modeling of neuropsychiatric diseases; Neurodegeneration and Aging. Radiology and statistical analysis of brain metabolites during normal aging and pathological animal models of Neurodegenerative Disease under conditions of caloric restriction - - George Perry, Ph.D., Adam Bogart, Ph.D., Ralph Sherman, B.S., Alex Diaz, Ph.D., & Ferez Nallaseth, Ph.D. & Sina Varmaghani, M.Sc. (Group Leader - Adam Bogart, Ph.D.).

Affiliations: Behavioral Neuroscientist (MRI), University Hospital of Lexington; Sanders-Brown Center on Aging

Contact Telephone Numbers and Email Addresses: 845-325-3049 (Mobile); abogart@kent.edu

Websites: https://www.researchgate.net/profile/Adam_Bogart; linkedin.com/in/adam-bogart-phd-67b1505a

Biosketch: Dr. Adam Bogart’s interests are in both functional and structural neuroimaging (MRI) of the neuropsychiatric disorders. In 2010 Dr. Bogart was awarded a Doctorate (Ph.D.) in Behavioral Neuroscience (Experimental Psychology) at Kent State University at Kent, OH. Dr. Bogart then went onto hold a number of Research and Postdoctoral Fellowship positions in Neuropsychiatric diseases, Neuroimaging and MRI modeling of Neuropsychiatric diseases; Neurodegeneration and Aging at Frontline Universities and Research Institutions. Dr. Bogart currently works at the Behavioral Neuroscientist (MRI), University Hospital of Lexington; Sanders-Brown Center on Aging. Furthermore it can be elaborated that his interests cover Neuropsychiatric diseases, Neuroimaging and MRI modeling of Neuropsychiatric Diseases; Neurodegeneration and Aging. D. Bogart also applies Radiology and statistical analysis of brain metabolites during normal aging and pathological animal models of neurodegenerative disease under conditions of caloric restriction. As underlying causes of Brain Cancers and Neurodegenerative Diseases (NGD e.g. affecting protein folding) lie in mutations inserted into the genome, we anticipate that with his vast experience in these areas, Dr. Bogart will make significant contributions to the core mission of the LSINJ. In his role of Chief of Imaging Operations (CIO), Chief of Statistical and Mathematical Operations (CISMO) as well as a Member of the focus group in the LSINJ on Neurosciences, etc. Dr. Bogart will play a foundational role. The combination of his expertise along with that of others members will drive preemption of disease lesions and eventually represent he only real cure for intractable disease states such as Neurodegenerative diseases.

Detailed Biosketch: (Scroll down to the profile: LSINJ.Detailed BioPic.10.30.18.pdf )

John Catanzaro, M.D.

(On sabbatical as of 7.15.2019)

Position and Role in LSINJ: Vice President for Oncology, Diagnostic and Precision Medicine Initiatives of the LSINJ; Head Baseball Coach

Interests: Cancer Hallmark Analytics and Immunocentrics a Biointelligence, Diagnostic and Therapeutic Applications, model and mission of architecting patient compatibility precision medicine; Aviation & Baseball;

Member of Working Group in LSINJ and Group Leader: on diagnostics, post-mutational therapies and pre-mutational causes of Cancer - failures of Chromosome Biology inducing Genetic Lesions; metastasis, etc..; Co-Director of liaising with Pharmaceutical and Biotechnology enterprises.

Affiliations: Co-Founder / CIO at NEO7 Cancer Hallmark Analytics and Immunocentrics

Contact Phone Numbers and Email Addresses: 2067185467 (Mobile) ; drjohnhwi@gmail.com

Websites: https://mx.linkedin.com/in/john-catanzaro-0908567

Biosketch: John Catanzaro was founder and CEO of a cancer institute that innovated patient-precision genetically matched immunopeptides to train defense cells to eradicate very advanced cancers with successful outcomes.

He is currently CISO (Chief Intelligence Strategic Officer) of NeoImmuno and Concierge Therapeutics two new emerging companies focusing in on precision / personalized analytics, immunocentric design and biointelligence theory. The focus is both on diagnostic and therapeutic applications, with the implementation model and mission of architecting patient compatibility precision medicine based treatment innovations and designs.

Previous experience includes founder and cofounder of two genetic testing companies. He was clinically active as cancer center founder and director (physician) in integrative oncology for over 20 years.

Dr. Catanzaro is currently an active consultant in precision-based biosciences including molecular and immune applications.

In his role as Vice President for Oncology, Diagnostic and Precision Medicine Initiatives of the LSINJ Dr. Catanzaro will play a foundational role. The combination of his expertise along with that of other members will drive preemption of disease lesions and eventually represent the only real cure for intractable pathological states such as Cancers and Neurodegenerative diseases.

A more complete account of the various contributions made by Dr. John Catanzaro is available through his profile on LinkedIn:

https://mx.linkedin.com/in/john-catanzaro-0908567

Jon de Borbón de Rojas

(Inactive as of 11.09.2019)

Position and Role in LSINJ: Vice President of Clinical Research Operations and Drug Delivery Operations of the LSINJ.

Interests: Molecular Biology, Biophysics, Biochemistry; International Finance; Emergency Pre-hospital Care; Advance Postgraduate Management

Member of Working Group in LSINJ and Group Leader: Liaison with Pharmaceutical Industries, Biotechnology and Drug Development Space; Educational initiatives.

Affiliation(s): Chief Research Officer of C3 Incorporated (current); as President and CEO of WCCT Global which was another Pharmaceutical Corporation

Contact Telephone Numbers and Email Addresses:

Phone Number: -

Email: to_jon@icloud.com

Websites: https://c3internationalinc.com/ ;

Detailed Information Link: (to be posted)

https://www.linkedin.com/in/jon-de-borb%C3%B3n-de-rojas-66713b63/

Biosketch: Jon de Borbón de Rojas is the Chief Research Officer (CRO) of C3 Incorporated, which is a Pharmaceutical corporation in Orange County, California. He oversees this research mission posted on the C3 site:https://c3internationalinc.com/

"The Mission of C3® International, Inc. is to manufacture the unique Intellectual Property forIdrasil™; A disruptive advancement in the standardization and titration for Hepatic delivery of natural, whole and active Cannabinoids, in a divisible tablet that is Rx only & major Insurance Reimbursable, for Quality of Life (QoL)" Jon de Borbón de Rojas has also served as President and CEO of WCCT Global which was another Pharmaceutical Corporation designed to facilitate ethnic bridging of clinical trials.

Jon de Borbón de Rojas has an eclectic background. He was enrolled in Molecular Biology, Biophysics, Biochemistry, at Florida International University in Miami. Mr. de Borbón de Rojas majored in International Finance to graduate from Barry University, in Miami Shores, FL, in 2011. Jon also undertook studies to train Physicians and Scientists in Emergency Pre-hospital Care at the David Geffen School of Medicine at UCLA. Finally majoring in Advance Postgraduate Management at the Stanford University Graduate School of Management in Palo Alto California. Jon is experienced in promoting the Public Interest in Health care. In addition, he has executed administrative responsibilities at several levels in the Pharmaceutical Industry. In addition he has multiple licenses in administering Life Support the medical field. CRO Jon de Borbón de Rojasis is highly accomplished with a membership in 21 organizations having completed 12 courses in medical or health services, clinical research associations, marketing, management and regulatory activities as well as promotion of civic causes.

Jon has a broad spectrum of experience in science and health services as well as through his administrative experiences at in the pharmaceutical industry. He has much to contribute to the Life Sciences Institute of New Jersey. Both in tangible and in intangible ways of cross-cultural leadership, particularly, in an institute such as the LSINJ. The LSINJ by definition not only has an international membership, but one that is globally situated.

A more complete description of contributions by Jon de Borbón de Rojas may be found on his profile on LinkedIn:

https://www.linkedin.com/in/jon-de-borb%C3%B3n-de-rojas-66713b63/

Bradley Droessler, BS

(Inactive as of 11.09.2019)

Position and Role in LSINJ: Vice President – Chemistry (Scientific Research Decisions - Chemistry); Vice President - Discovery Chemistry Research and Development (organic medicinal drugs for therapies in Neuroscience and Neuropathologies); Co-CPL (Co - Chief of Pharmaceutical Liaison – USA); Director of Chemical Biology group. Coordination of Ancillary LSINJ goals as Co - Group Leader for Public Science Education in USA) goals in meeting Pharmaceutical, Educational and Health needs of Inner Cities in the USA and Developing Nations of Africa (based in Morocco and Nigeria).

Interests: Discovery Chemistry Research & Development, Neuroscience, Organic-Medicinal Chemistry, Pharmaceutical – Biotech Industries.

Member of Working Group in LSINJ and Group Leader: Co-Group of Group Leader for Pharmaceutical Liaison – Developing Societies; Co - Group Leader for Public Science Education in Developing Societies consisting of George Perry, Ph.D., Alex Diaz, Ph.D., Kholis Audah, Ph.D., Tony Lai, MD, M.B.B.S., FACOG, Hafiz S. Yahya, Ph.D., Ferez S. Nallaseth, Ph.D., Syed M. Ahmed, Ph.D., Liz Parrish, CEO/CMO and Nirmali Wijegoonawardana, Ph.D., Asmaa Rabit, M.D., and Lucy Muniz, MD (Co-Group Leader with others; International representation: U.S.A., India, Pakistan, Jamaica, Sri Lanka, Morocco, Nigeria and Argentina); Coordination of Ancillary LSINJ goals as CPSE – DS goals in meeting Pharmaceutical, Educational and Health needs of Developing Nations of Africa (based in Morocco and Nigeria); Vice President and Group Leader – Chemistry (Scientific Research Decisions - Chemistry); Vice President and Group Leader - Discovery Chemistry Research and Development (organic medicinal drugs for therapies in Neuroscience and Neuropathology) comprising of George Perry, Ph.D., Ralph Sherman, B.S., Adam Bogart, Ph.D., Kholis Audah, Ph.D. and Alex Diaz, Ph.D.; As VP – Chemistry, Bradley Droessler coordinates with Ralph Sherman (Chief of Biophysics Operations); Chief of Technology Transfer Operations; Chief of Electronics Operations; Chief of Biophysics Technology Transfer - Central Nervous System (EEG) Thermodynamics; Group Leader in Groups on Biophysics, Electronics and Technology Transfer Operations; Member of the Group on Neurosciences, Neuropathology, Neuropsychiatric Diseases, Experimental Psychology, Anoxia Tolerance, Thermodynamic States of Hypoxic Neurophysiological Systems. As VP – Chemistry, Bradley Droessler coordinates with Medicinal Chemists Dickson Musa, Ph.D. and Kholis Audah, Ph.D. who are respectively exploiting Biodiversity in Nigeria (Africa) and Indonesia (Asia).

Affiliation(s): Independent Consultant & Chemist (Current Position); Novel Medicinal Drug Discovery R & D - Collaborative Group (Emeritus); CSS corporation (Emeritus); Eli Lilly and Company (emeritus); University of Wisconsin in Madison (Emeritus).

Contact Telephone Numbers and Email Addresses:

Phone Number:

Email: sci.rd.consult@gmail.com

Websites: linkedin.com/in/bradleydroessler

Biosketch: Consultant Bradley Droessler is introduced to the LSINJ as its first highly accomplished and genuine Chemist. Principal Investigator Droessler's contributions span the range made as a Team Leader and a Principal Investigator in Pharmaceutical and Industrial settings as well as in the role of an Independent Consultant. Of relevance to interests in the LSINJ Bradley Droessler's work in Discovery Chemistry Research and Development has led to organic medicinal drugs for therapies in Neuroscience and Neuropathology. He has been awarded a slew of Fellowships and other Awards for his contributions to our understanding of Fundamentals of Chemical Processes and their role in Biological Systems. Some of his leadership positions and relevant contributions follow:

From 2002 to 2010 Bradley Droessler was "the Chief Scientist and Manager of R&D into novel therapeutically relevant molecules, Principal Patent Author-Inventor of NCE's as well as branded, generic, and clinical process chemistry optimization IP." Bradley directed these discoveries as the Chief Scientist, Chemist and Principal Investigator at Novel Medicinal Drug Discovery R & D - Collaborative Group.

From 2002 to 2008 Bradley Droessler was the Chief Scientific Officer, Chief Scientist, and Global Operations Manager for CSS corporation. As CSO of CSS Bradley was "responsible for companywide management of a team of scientists and chemists, as well as full strategic and scientific oversight of all company products, services, and programs."

From 1999 to 2003 Bradley Droessler worked as a Biological/Chemist at Eli Lilly and Company. At Eli Lilly and Company Brad's "research covered early to mid stage discovery chemistry research with a focus on Serotonergic, Dopaminergic, and poly-receptor subtype selective ligands as therapeutics for central nervous system (CNS) disease targets."

Bradley Droessler's education in Chemistry was acquired at the University of Wisconsin in Madison commonly recognized as the foremost research institution and university for all dimensions of the field of Chemistry. It is also a foremost University for research in the field of Genetics. The contributions of University Faculty in these 2 areas have even been recognized with Nobel Laureates awarded e.g. to to Dr. Hargobind Khorana (jointly with Dr. Marshall Nirenberg) for elucidating the process by which genetic codes were enzymatically converted to protein sequences. Chemist/Consultant Bradley Droessler received his Bachelor's degree (B.S.) in Chemistry followed by a slew of advanced training diplomas in e.g. Analytics, Synthesis, Spectroscopy, and Medicinal Chemistry areas of chemistry from the University of Wisconsin at Madison.

A more complete profile for Chemist and Principal Investigator Bradley Droessler may be accessed on LinkedIn:

https://www.linkedin.com/in/bradleydroessler/

Bradley Droessler has much to contribute to the LSINJ, in his roles as a scientist, an administrator, a member of the pharmaceutical and chemical societies. However of most importance as someone with a lifetime of experience in Chemistry he brings the only genuine understanding of the chemical dimension of the the contemporary foundational triad of physics, chemistry and biology. Which along with computational sciences is driving advances in the understanding of the brain/mind, development, all the OMES and the biophysical forces shaping and driving development and evolution among many other advances in the Life Sciences!

Detailed Information Link: (Scroll down to the profile: (LSINJ.Detailed BioPic.10.30.18.pdf )

Edye (Taylor) Edens, JD

(On sabbatical as of 9.15.2019)

Position and Role in LSINJ: Vice President for Legal Affairs & Scientific Research Governance; Liaison with NIH and other regulatory and funding bodies.

Interests: attorney with an international human rights, ethics, and health law background who has Seniority in Research Compliance, Misconduct and site-level compliance work as it relates to QA, monitoring, and auditing (particularly oncology); Human Rights Advocate and Bioethicist in the United States and Kenya .

Member of Working Group in LSINJ and Group Leader: Cancer, Neurodegenerative (Alzheimer's Disease); Legal and Regulatory/Compliance Arms.

Affiliations: Currently: First Class Solutions, Indianapolis, IN; Formerly: Indiana University; IU simon Cancer Center, Indianapolis, IN.

Contact Telephone Numbers and Email Addresses: (317) 340 2906 (Home); edye.edens@firstclasssolutions.com

Websites: firstclasssolutions.com/consulting.htm (Company Website); firstclasssolutions.com/staff.htm (Company Website)

Biosketch: Prof. Edye Edens is a licensed attorney with an international human rights, ethics, and health law background who is a Senior Research Compliance Consultant with First Class Solutions providing a new line of consulting services focused on research compliance and life sciences. Legal consulting services include but are not limited to: research administration, healthcare compliance, grants/contracts to IRB, COI, education, privacy, HIPAA, FDA, AAHRPP, misconduct and site-level compliance work as it relates to QA, monitoring, and auditing (particularly oncology). Services are provided as education and training, program creation and management, organizational change management, or even as a complete outsourcing solution.

Previously, while in-house for a decade at Indiana University, she focused on the role of human rights in health and worked at the Human Subject Offices on both the Bloomington and Indianapolis campuses, the Indianapolis Grant Services office, Clinical Research Compliance Office and the Research Integrity Office. In 2016, she became the first Quality and Compliance Manager for the IU Simon Cancer Center over all aspects of compliance related to all clinical trials performed at IUSCC, before departing for the consulting world.

The vast and varied experience of Prof. Edens spans her responsibilities as a Research Compliance Consultant, Executive Coach, Experienced Life Sciences Attorney, Compliance and Ethics Attorney at the IU Simon Cancer Center as well as her former role as a Professor of Law at Indiana University, Indianapolis, Indiana. Furthermore Prof. Eden’s role as a Human Rights Advocate and Bioethicist in the United States and Kenya add indispensable International experience to her already substantial repertoire of qualifications. In these positions Prof. Edens will be invaluable in assisting the LSINJ meet its legal, ethical and administrative responsibilities while retaining the bulwark and thrust of its mission in preempting genetic disease lesions. One that can only be met by engaging Citizen Scientists.

A complete description of contributions and accomplishments of Professor Edye (Taylor) Edens is available on her LinkedIn Profile:

https://www.linkedin.com/in/edyetedens

Lucy Muñiz, M.D.

(Former Board Member as of 08.11.2019)

Position and Role in LSINJ: Vice President for Marketing and Communications Co-Chief Marketing Officer (CMaO); CPSE – USA (Chief of Public Science Education in the USA); Co-Group Leader on Educational Outreach of the LSINJ in the Developing World – South America & Argentina; Co-Group Leader on Medical Outreach of the LSINJ in the Developing World – South America & Argentina; Co - Group Leader on Pharmaceutical Outreach of the LSINJ in the Developing World – Argentina & South America.

Interests: Marketing, Medicine; Neuroscience; BioInformatics; Policy Issues while Sociopolitics.

Member of Working Group in LSINJ and Group Leader: Co-Group of Group Leader for Pharmaceutical Liaison – Developing Societies; Co - Group Leader for Public Science Education in Developing Societies consisting of George Perry, Ph.D., Alex Diaz, Ph.D., Kholis Audah, Ph.D., Tony Lai, MD, M.B.B.S., FACOG, Hafiz S. Yahya, Ph.D., Ferez S. Nallaseth, Ph.D., Syed M. Ahmed, Ph.D., Liz Parrish, CEO/CMO, Nirmali Wijegoonawardana, Ph.D., Asmaa Rabit, MD and Lucy Muñiz, M.D. (Co-Group Leader with others; International representation: U.S.A., India, Pakistan, Jamaica, Sri Lanka, Morocco, Nigeria, Argentina – Asia, South America, Africa, North America); Coordination of Ancillary LSINJ goals as CPSE – DS (Chief of Public Science Education in Developing Societies, Africa, Nigeria, Morocco and Argentina); Co - Group Leader for Public Science Education in Developing Societies of Africa with Asmaa Rabit, MD) goals in meeting Pharmaceutical, Educational and Health needs of Developing Nations of Africa (based in U.S.A., India, Pakistan, Jamaica, Sri Lanka, Morocco, Nigeria, Argentina – Asia, South America, Africa, North America).

Affiliation(s): Owner/Editor of The Pharmaceutical Marketing Group (TPMG); Pharma Marketing Group on LinkedIn representing PharmaMKT; University of Buenos Aires (Emeritus).

Contact Telephone Numbers and Email Addresses:

Phone Number: +54.9.11.6265.0005 (Mobile)

Email: lucia.muniz@gmail.com

Websites: https://www.linkedin.com/in/luciamuniz/ ; linkedin.com/in/luciamuniz

; https://www.linkedin.com/groups/28204

Biosketch: Dr. Lucy Muñiz currently is the Owner/Editor of The Pharmaceutical Marketing Group (TPMG). As the largest and first Pharma Marketing Group on LinkedIn representing PharmaMKT the marketing agency that Lucy leads, advises several prominent pharmaceutical corporations on "brand strategy, content marketing, social media marketing in pharmaceuticals and healthcare."

Dr. Lucia Muñiz is a Physician who earned her (medical) Medica degree in the field of Medicina in 1994 at the University of Buenos Aires, Argentina. Lucy Muñiz currently resides in Buenos Aires and commutes to New York City on a monthly basis. Dr. Lucy Muñiz has delivered lectured in Neuroscience and BioInformatics at the University of Buenos Aires. However, Dr. Lucia Muñiz had diversified her professional background into Policy Issues while making sociopolitical and other contributions that complement her background in Medicine. Lucy holds several Masters degrees that were earned in 2002 and 2008.

A complete profile for Dr. Lucy Muñiz as well as PharmaMKT can be accessed via her LinkedIn profile: https://www.linkedin.com/in/luciamuniz/; https://www.linkedin.com/groups/28204

The Life Sciences Institute of New Jersey expects to be enriched by this wide range of experience of Dr. Lucy Muñiz. This experience spans scientific, medical, cultural, social, public relations and administrative domains. In particular the vast experience that Lucy brings from the field of community relations would be an immense asset to the LSINJ in communicating its core message to Global Scientists and Citizen-Scientists. This effort would complement the roles played by Board Members, CEO Liz Parrish and Prof. Nirmali Wijegoonawardana among others. All of which is essential to the contributions of the LSINJ as well as its survival as a credible Private Foundation for 'Preempting Genetic Diseases and Birth Defects.'

We anticipate that Dr. Lucia Muñiz will play a prominent role in directing the LSINJ in meeting its core research and societal goals. Furthermore, in her roles as Vice President for Science – South America and CPL (Chief of Pharmaceutical Liaison – Developing Societies in South America), Co - Group Leader for Public Science Education in Developing Societies in South America in collaboration with CEO Liz Parrish, Dr. Asmaa Rabit and Dr. Kholis Audah as well as personnel with similar international backgrounds in developing nations will be in a good position to coordinate the socioeconomic, civic and educational goals of the LSINJ in meeting the Pharmaceutical, Educational and Health needs of Developing Nations.

Detailed Information Link: (Scroll down to the profile: (LSINJ.Detailed BioPic.10.30.18.pdf )

George Perry, Ph.D.

(Former Board Member as of 09.29.2020)

Position and Role in LSINJ: Vice President for Executive Decisions; Group Leader – Group of Neurosciences, Neuropathology, Neuropsychiatric Diseases, Experimental Psychology, Anoxia Tolerance, Thermodynamic States of Hypoxic Neurophysiological Systems; Co-Group Leader on Educational Outreach of the LSINJ in the USA; Co-Group Leader on Medical Outreach of the LSINJ in the USA; Co-Group Leader on Pharmaceutical Outreach of the LSINJ

Interests: Areas of Specialization: Alzheimer's disease; Neurobiology; Oxidative stress:

Dr. Perry’s studies are focused on the mechanism of formation and physiological consequences of the cytopathology of Alzheimer disease. The lab has shown that oxidative damage is the initial cytopathology in Alzheimer disease. They are working to determine the sequence of events leading to neuronal oxidative damage and the source of the increased oxygen radicals. Current studies focus on the:

  1. role of redox active metals in mediating prooxidant and antioxidant properties

  2. mechanism of phosphorylation control of oxidative damage to neurofilament proteins

  3. mass spectrometry analysis of protein metal binding and crosslinking

4. Click here for a list of publications.

Member of Working Group in LSINJ and Group Leader: Group Leader – Group of Neurosciences, Neuropathology, Neuropsychiatric Diseases, Experimental Psychology, Anoxia Tolerance, Thermodynamic States of Hypoxic Neurophysiological Systems; Co-Group Leader on Educational Outreach of the LSINJ in the USA; Co-Group Leader on Medical Outreach of the LSINJ in the USA; Co-Group Leader on Pharmaceutical Outreach of the LSINJ; Group of Developmental Biology; Member – Group on Sex Determination and Gametogenesis, Reproductive Biology’ Evolutionary Genetics, Speciation, Chromosome (Genome Biology);

Affiliations: Professor, Semmes Foundation Distinguished University Chair in Neurobiology, UTSA – The University of Texas at San Antonio, San Antonio, TX; Brain Health Consortium ; UTSA Neurosciences Institute; Dean, Emeritus, College of Arts and Sciences, UTSA, San Antonio, TX

Contact Telephone Numbers and Email Addresses: (210) 458-8660; george.perry@utsa.edu

Websites: https://www.utsa.edu/biology/faculty/GeorgePerry.html; https://www.linkedin.com/in/georgeperry/:;Lab website

RTRN ResearchersWikipedia

Biosketch: Prof. George Perry was awarded his doctorate (Ph.D.) in Marine Biology by the renowned Scripps Institution of Oceanography, San Diego CA and a B.A. in Zoology at the University of California, Santa Barbara, CA. Professor Perry currently holds the Semmes Foundation Distinguished University Chair in Neurobiology and is the Dean, Emeritus, College of Arts and Sciences, UTSA. Prof. Perry has held highly productive positions at marquee Research Institutes and Universities across the United States including at, Baylor College of Medicine (BCM); Stanford University; Allan Hancock College; Marine Biological Laboratory; University of California Santa Barbara UCSB; Scripps Institution of Oceanography; Case Western Reserve University, CWRU. These positions have resulted in an enormous volume of contributions totaling 1136 publication(s) (access Prof. Perry’s list of publications here ). However the roles that Prof. Perry has played over decades go far beyond this productivity in the scientific literature and extend into leadership positions in education, biotechnological, pharmaceutical and medical industries, research communities, editorial positions and society at large. Beyond which he has strongly promoted counter-exclusionary editing (amounting to censorship) and strongly advocated for the unbiased review of papers and scientific literature (https://www.webmedcentralplus.com/chief_foreword ). This advocacy is consistent with First Amendment protections of the Constitution of the United States which necessarily also applies to scientific publications. Prof. Perry’s scientific studies are focused on the mechanism(s) of formation and physiological consequences of the cytopathology of Alzheimer disease. The lab of George Perry has shown that oxidative damage is the initial cytopathology in Alzheimer disease. They are working to determine the sequence of events leading to neuronal oxidative damage and the source of the increased oxygen radicals. Reactive oxygen species (ROS) are generated as byproducts of and respiration in mitochondrial electron transport as well as in general metabolism and toxic agents in the environment. Distinct species of ROS are catabolized and eliminated enzymatically. However, those ROS that escape catabolism can oxidize proteins and nucleic acids consequently inducing genetic lesions (mutations). These lesions are repaired or preempted by various mechanisms e.g. those coping with DNA repair, replication and recombination. Thus Prof. Perry’s lab interest directly dove tails with the core mission of the LSINJ. Furthermore, Prof. Perry holds various positions in the LSINJ as Vice President (Executive Decisions) and Group Leader or Member (of multiple groups), as well as having affiliations in academia and industry. This puts Prof. Perry in the excellent positions of promoting and driving the scientific, educational, medical, pharmaceutical and societal objectives of the LSINJ at home and abroad.

Detailed Biosketch: (Scroll down to the profile: LSINJ.Detailed BioPic.10.30.18.pdf )

John Torday, Ph.D.

(On Sabbatical as of 5.12.2019)

Position and Role in LSINJ: Vice President for Scientific Research decisions; Co - Group Leader of First working group: Group on Evolutionary Genetics, Reproductive Biology and Preemptive Medicine; Co-Group Leader of First working sub- group: Sub-group on Evolutionary Medicine; Co-Goup Leader of Developmental Biology and Genetics; Second working group: Group on Sex Determination and Gametogenesis; Group of Neurosciences, Neuropathology, Neuropsychiatric Diseases, Experimental Psychology, Anoxia Tolerance, Thermodynamic States of Hypoxic Neurophysiological Systems; Co-Group Leader: Group on Sex Determination and Gametogenesis, Reproductive Biology’ Evolutionary Genetics, Speciation, Chromosome (Genome Biology)

Interests: Central Theory of Biology; mechanisms in Development and in Evolutionary Medicine; sexual dimorphism of the response of the lung to glucocorticoid treatment; fetal physiology and mechanisms determining pattern formation; Neutral Lipid Trafficking. Serial developmental and phylogenetic cell-cell interactions wrt homeostatic control of alveolar physiology; Parathyroid Hormone-related Protein; endothermy and homeothermy, the thyroid, externalization of the testes, and even the nature of consciousness as the endogenization of the external environment.

Member of Working Group in LSINJ and Group Leader: First working group: Group on Evolutionary Genetics, Reproductive Biology and Preemptive Medicine (John Torday, Ph.D., George Perry, Ph.D.; Ferez S. Nallaseth, Ph.D., Tony Lai, MD, M.B.B.S., FACOG and Liz Parrish); Co-Group Leader of First working sub- group: Sub-group on Evolutionary Medicine (John Torday, Ph.D., George Perry, Ph.D.; Ferez S. Nallaseth, Ph.D., Tony Lai, MD, M.B.B.S., FACOG and Liz Parrish, CEO; Kholis Audah, Ph.D.); Second working group: Group on Sex Determination and Gametogenesis John Torday, Ph.D. & Ferez S. Nallaseth, Ph.D. and George Perry, Ph.D. and Tony Lai, MD, M.B.B.S., FACOG (Co-Group Leaders: John Torday, Ph.D. and Ferez S. Nallaseth, Ph.D.); Group of Neurosciences, Neuropathology, Neuropsychiatric Diseases, Experimental Psychology, Anoxia Tolerance, Thermodynamic States of Hypoxic Neurophysiological Systems; Member Co-Group Leader of Group of Developmental Biology; Member – Group on Sex Determination and Gametogenesis, Reproductive Biology’ Evolutionary Genetics, Speciation, Chromosome (Genome Biology), Co-Group Leaders: George Perry, Ph.D., John Torday, Ph.D. & Ferez S. Nallaseth, Ph.D. ).

Affiliations (Past & Present): Professor in Residence at UCLA (present); Professor, University of Maryland; Assistant Professor at Harvard University.

Contact Telephone Numbers and Email Addresses: john.torday (Skype); jtorday@labiomed.org ; John.Torday@blogger.com (Blog)

Websites: https://www.eeb.ucla.edu/evmed/indivfaculty.php?f=torday; https://labiomed.org/john-s-torday-phd;

Biosketch: Prof. John Torday did his graduate and post-graduate work at some of the leading Universities in education, research and science. John has himself continued this tradition in leading universities as a Bench or Research Scientist, Professor, Educator and Public figure for more than 50 years. Prof. John Torday was awarded his doctorate (Ph.D.) and Masters (M.Sc.) at McGill University in 1971 and 1974 and held a Postdoctoral Fellow’s position at the University of Wisconsin-Madison in 1968. Prof. Torday has held highly productive faculty positions at marquee Research Institutes and Universities across North America which led to his ascent up the academic ladder to its pinnacle. These positions included as, Assistant Professor of Pediatrics and Physiology at Harvard University in Pediatrics & Physiology from 1961 to 1968, as a Professor of Pediatrics and Ob-Gyn at the University of Maryland from 1991 to 1998 and finally as a Professor of Pediatrics, Ob-Gyn and Evolutionary Medicine at UCLA from 1991 to 1999. He has been continuously funded from 1998 to the present posting. These positions have resulted in a large volume of contributions totaling 190 publication(s), 3 monographs and 1 Professional Lecture series.

Prof. Torday initially studied fetal physiology and mechanisms determining pattern formation through the effects of glucocorticoids on lung development by exploiting the biology of lung surfactant as cell-cell interactions. Subsequently, he studied the sexual dimorphism of the response of the lung to glucocorticoid treatment, leading to further insights to the mechanism of glucocorticoid action on the lung. This pursuit led John to the seminal discovery of Neutral Lipid Trafficking. Serial developmental and phylogenetic cell-cell interactions involved in that process gave fundamental insight to the homeostatic control of alveolar physiology. With the elucidation of the underlying cellular-molecular mechanisms, this process now explains many aspects of lung alveolar structure and function that were previously untenable. The implication of Parathyroid Hormone-related Protein in this process led to fundamental insights to the evolution of the lung, exploiting the cell-cell interactions to reverse-engineer the lung all the way back to its unicellular origins as cholesterol insertion in the cell membrane. Because of the commonalities between the lung and other tissues and organs at the cellular/molecular level, the lung evolution scenario led to insights into the evolution of vertebrate physiology in general. With such knowledge of the ‘history’ of vertebrate evolution, narrated from its beginnings for the first time instead of ‘reasoning after the fact’ has afforded elucidation of such physiologic traits as endothermy and homeothermy, the thyroid, externalization of the testes, and even the nature of consciousness as the endogenization of the external environment. Because of the predictive value of this model of vertebrate evolution, a Central Theory of Biology was developed for the first time.

Prof. Torday holds various positions in the LSINJ as Vice President (Scientific Decisions) and Group Leader or Member (of multiple groups), as well as having affiliations in academia and industry. With his background particularly in ontogeny of mechanisms in Development and in Evolutionary Medicine Prof. John Torday is expected to play a central and role in propelling the LSINJ forward in its core mission (sketched on this Landing Page).

Although John has taken a leave of absence from the LSINJ which is akin to a sabbatical we look forward to his many contributions as well as working actively with him on his return to the LSINJ.

Detailed Biosketch: (Scroll down to the profile: LSINJ.Detailed BioPic.10.30.18.pdf )

Jose Thekkiniath, Ph.D.

Position and Role in LSINJ: Vice – President of LSINJ for Microbiology, Parasitology and Drug Development: Co- Group Leader - Microbiology and molecular biology, Drug discovery, efflux pumps, infectious diseases, diagnosis of vector borne infectious diseases; histochemistry, cytochemistry and cell & tissue biology

Interests: Microbiology and molecular biology, Drug discovery, efflux pumps, infectious diseases, diagnosis of vector borne infectious diseases

Member of Working Group in LSINJ and Group Leader: Group Leader for Group of Microbiology and molecular biology, Drug discovery, efflux pumps, infectious diseases, diagnosis of vector borne infectious diseases; Co-Group Leader with VP Ralph Sherman, B.S.: in Groups on Biophysics, Electronics and Technology Transfer Operations; Co-Group Leader for Group of Pharmaceutical Liaison – Developing Societies; Co - Group Leader for Public Science Education in Developing Societies consisting of George Perry, Ph.D., Alex Diaz, Ph.D., Kholis Audah, Ph.D., Tony Lai, MD, M.B.B.S., FACOG, Hafiz S. Yahya, Ph.D., Ferez S. Nallaseth, Ph.D., Syed M. Ahmed, Ph.D., Liz Parrish, CEO/CMO and Nirmali Wijegoonawardana, Ph.D. (Co-Group Leader with others; International representation: U.S.A., India, Pakistan, Jamaica, India and Sri Lanka).

Affiliation(s): Senior Scientist at Fuller Laboratories in California (2019 – present); Postdoctoral Fellow at Yale School of Medicine (2013 - 2019 ); Postdoctoral Fellow at University of Massachusetts Medical School ( ); Editor at Folia Histochemica et Cytobiologica (2015 – present); reviewer at: PLoS One, Journal of Clinical Medicine, Journal of Fungi, Pathogens, Antibiotics, Infection and Drug Resistance, Clinical Interventions in Aging and Current Microbiology (2015 - present); Texas Tech University (2006 – 2013); the Indian Agricultural Research Institute in New Delhi, India (2001 – 2004)

Contact Telephone Numbers and Email Addresses:

Phone Number: 806-5437690

Email: jose.joshua@gmail.com; jose.thekkiniath@fullerlabs.net

Websites: https://www.linkedin.com/feed/?trk=guest_homepage-basic_nav-header-signin

; https://www.researchgate.net/profile/Jose_Thekkiniath

; https://www.ncbi.nlm.nih.gov/pubmed/?term=Thekkiniath

Biosketch:

Dr. Jose Thekkiniath has been appointed to the position of a Senior Scientist at the Fuller Laboratories in California since October 2019 when he initiated his work. He is currently working on developing novel diagnostic tests for vector-borne infectious diseases. Dr. Thekkiniath has more than 13 years of experience in basic life sciences research with major focus on microbiology, immunology and molecular biology. Dr. Thekkiniath is a highly talented scientist with a strong record of accomplishments in studies of pathogens that affect plants, animals and humans. He is well established in microbiological research, having completed several independent research projects while being included in collaborations.

Dr.Thekkiniath earned his PhD from Texas Tech University (TTU) in 2013 in Biological Sciences. Jose's research has spanned stress responses of pathogens infecting organisms across the evolutionary spectrum. As a Graduate student at TTU, Dr. Thekkiniath taught microbiology involving both lecture and laboratory classes while also training several undergraduate researchers in the laboratory from 2006 to 2013 - a period of 7 years. Dr. Thekkiniath has been awarded the prestigious ICAR (Indian Council for Agricultural Research) Junior Research Fellowship for Masters (M.Sc) program in Microbiology at the Indian Agricultural Research Institute in New Delhi, India (a leading national institute for agricultural research, education and extension) where he worked from 2001 to 2004.

After leaving Texas Tech, Dr. Thekkiniath joined Yale School of Medicine and University of Massachusetts Medical School for his Postdoctoral research work where he worked on numerous projects including the mechanisms of pathogenesis and immunity in several organisms including parasites of humans such as the agent of babesiosis and malaria (protozoan parasites that live in red blood cells) and has been contributed to developing anti-fungal, and anti-parasitic therapies. Much of Jose's work as well as his contributions at Yale and UMass Medical School can be accessed through this link: https://www.researchgate.net/profile/Jose_Thekkiniath

Dr. Thekkiniath has been demonstrated a track record of scientific success (publications, book chapters, patents, grants and awards). He has been an active member of American Society for Microbiology (ASM) (2006- present) while being awarded travel grants for making presentations of his research at the ASM annual meetings. He has been a member of American Association for the Advancement of Science (2007-present) and an associate member of Sigma Xi, The Scientific Research Society (2011-present). Dr. Thekkiniath has been an invited speaker for International Babesiosis meeting in 2018 and 2019. Dr. Thekkiniath has also been Editor for the journal, Folia Histochemica et Cytobiologica (an international, journal publishing articles in the areas of histochemistry, cytochemistry and cell & tissue biology) since 2015. Additionally, he has been a reviewer for several peer-reviewed journals including PLoS One, Journal of Clinical Medicine, Journal of Fungi, Pathogens, Antibiotics, Infection and Drug Resistance, Clinical Interventions in Aging and Current Microbiology.

Jose is experienced in promoting the Public Interest in Health care. In addition, he has executed administrative responsibilities at multiple levels in the University system while working on areas with significance for the Pharmaceutical Industry. Dr. Thekkiniath has wide ranging administrative and research experience in science, teaching and health services. He has much to contribute to the Life Sciences Institute of New Jersey. Both in tangible as well as in intangible ways of cross-cultural leadership in an institute such as the LSINJ.

Detailed Biosketch: (to be updated – scroll down: LSINJ.Detailed BioPic.10.30.18.pdf )

Kim Van Vliet, Ph.D.

(Former Board Member as of 11.01.2019)

Position and Role in LSINJ: Director of LSINJ undertakings requiring Protein, Expression, Protein Chemistry, Structural Biology and Viral vectors

Interests: Proteomics, Mass Spectrometry and Chromatography; Protein, Expression, Protein Chemistry, Structural Biology and Viral vectors

Member of Working Group in LSINJ and Group Leader: (A) Group Leader: Working Group on Protein, Expression, Protein Chemistry, Structural Biology and Viral vectors consisting of George Perry Ph.D., Kholis Audah Ph.D., Dickson Musa Ph.D., Ferez S. Nallaseth PhD, Moyosola Otusanya MSc, Bradley Droessler, BS, Ralph Sherman, B.S. (B) Group for Pharmaceutical Liaison; Co - Group Leader for Pharmaceutical consisting of George Perry Ph.D., Kholis Audah Ph.D., Dickson Musa, Ferez S. Nallaseth Ph.D., Moyosola Otusanya M.Sc., Bradley Droessler, B.S., Ralph Sherman, B.S., Lucy Muñiz, M.D., Liz Parrish, CEO, John Catanzaro Ph.D., Tony Lai M.D., M.B.B.S., F.A.C.O.G.

Affiliation(s): Assistant Scientist, University of Florida in Gainesville

Contact Telephone Numbers and Email Addresses:

Phone Number: 352-281-4240 (Mobile)

Email: kimvanvliet2@gmail.com

Websites: linkedin.com/in/kim-van-vliet-phd-265475a ; http://msg.mbi.ufl.edu/bio-kim.html

Detailed Information Link: (To be Listed in the Biopic link at the bottom of the page)

Biosketch: Dr. Kim Van Vliet is a Biochemist on the Faculty of the University of Florida (UFL) in Gainesville specializing in Protein, Expression, Protein Chemistry and Structural Biology. Dr. Vliet has concentrated on the biology of viral particles, namely binding, replication and encapsidation of the viral particles (AAV and Poxvirus). Kim has concentrated on their application as vectors for delivering genes.

Dr. Kim Van Vliet earned her doctorate (PhD) at the University of Florida in 2007 in the fields of Molecular Genetics and Microbiology. After progressing through a Postdoctoral Fellowship at UFL from 2007 – 2011 she was promoted to her current rank of Assistant Scientist. Kim also earned a Master of (MS) degree at the Department of Biology and the Center for Molecular Biology and Biotechnology at Florida Atlantic University in Boca Raton from 1998 - 2001. Kim was among the most helpful, committed, informed and interesting conversationalists in subjects both in and peripheral to science. Kim maintained what amounted to a residence in the lab at FAU. We can find more about Dr. Kim Van Vliet on her LinkedIn profile:

https://www.linkedin.com/in/kim-van-vliet-phd-265475a/

Dr. Van Vliet's interests in Proteomics, Mass Spectrometry and Chromatography complements those of several other Board Members of the LSINJ so raising the possibility of productive collaborations. Kim's expertise with Protein Chemistry and Structural Biology, the biology of viral particles and holds much promise for the elevation of the depth of analyses represented by either distinct or confluent fields of research of BM of the LSINJ. Board Members of the LSINJ look forward to productive interactions with Dr. Kim Van Vliet.

Detailed Biosketch: (Scroll down to the profile: LSINJ.Detailed BioPic.10.30.18.pdf )

Rebecca Xu, Diploma for Allied Health & Biomedical Sciences (2022)

(Graduated from the LSINJ as of 8.31.2020)

Position and Role in LSINJ: Intern and Student Observer of the Proceedings of the Board of the LSINJ; Lead for Student Affairs

Interests: 'Interactions between the azathioprine drug and variants in the NUDT15 protein' ; 'The Orchid Organization is a community-based organization led by students whose purpose is to raise awareness about personal health and wellness; Intern at Rutgers, New Jersey Medical School in Newark, NJ; SMART Program at NJ Medical School, and taking a Rutgers gene sequencing course (WISE); published a scientific article on the Helyx Initiative blog, and founded a Helyx Initiative Central Jersey chapter

Member of Working Group in LSINJ and Group Leader: Group Member: Evolutionary Genetics of Speciation inducing dysfunctional regulation of Chromosome and Genome Biology; Structure/function and expression of RNA & Proteins from heterologous hosts; Virology and Microbiology (Microbial - Evolution, Ecology, Genetics); Molecular Genetics

Affiliation(s) and Positions: Middlesex County Academy for Allied Health Biomedical Sciences in Edison, NJ (2018 – 2022, expected Diploma); Founder and President of Orchid Organization, Student led Community Health Organization (2019 – present); Rutgers, New Jersey Medical School in Newark, NJ (2019 - 2020);

Contact Telephone Numbers and Email Addresses:

Phone Number: -

Email: rxu1166@gmail.com

Websites: (1) https://oasisa.github.io/The-Orchid-Organization/about-us.html; (2)http://njms.rutgers.edu/smart/app.cfm;(3)https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=&cad=rja&uact=8&ved=2ahUKEwjw7dGmhcTqAhX1l3IEHb83DD8QFjAEegQIDRAD&url=https%3A%2F%2Fem.rutgers.edu%2Fncp%2Fsearch%2FProgramDetails.aspx%3Fid%3D438%26src%3Dbrowse&usg=AOvVaw00pCpfq9nOa5DIxHdxxbry

Educational Institutions, Degrees: Middlesex County Academy for Allied Health Biomedical Sciences in Edison, NJ (2018 – 2020); Rutgers, New Jersey Medical School in Newark, NJ (2019 - 2020); Co – Founder/Vice President, The Orchid Organization, Student led Community Health Organization (2019 – present);

Biosketch: Ms Xu is currently graduating from Middlesex County Academy for Allied Health Biomedical Sciences in Edison, NJ, where she has trained from 2018 to 2020. She has also trained as an Intern at Rutgers, New Jersey Medical School in Newark, NJ.

Rebecca has recently been promoted to Founder/Vice President of The Orchid Organization. As she states 'The Orchid Organization is a community-based organization led by students whose purpose is to raise awareness about personal health and wellness.' She has co-Founded and has been working at the Orchid Organization since 2019.

https://oasisa.github.io/The-Orchid-Organization/about-us.html

Ms Xu is already an accomplished Scientist. To quote Rebecca ' the work on the interactions between the azathioprine drug and variants in the NUDT15 protein' has been presented in conferences and won awards.

NucleotidetriphosphatediphosphataseNUDT15

For the ‘NUDT15 research we used datasets, DNA sequencing, and protein analysis tools to achieve significant findings despite our situation. Once quarantine is lifted, I may be able to use school laboratory equipment and I can actively pursue laboratories nearby.'

A relevant extract of Ms Rebecca Xu's Profile on LinkedIn states: 'My experience includes a research project on a potential drug interaction between NUDT15 mutated variants and the azathioprine drug (this won the 2020 International Youth Research Seminar), attending the SMART Program at NJ Medical School, and taking a Rutgers gene sequencing course (WISE). I have published a scientific article on the Helyx Initiative blog, and founded a Helyx Initiative Central Jersey chapter.'

http://njms.rutgers.edu/smart/app.cfm

https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=&cad=rja&uact=8&ved=2ahUKEwjw7dGmhcTqAhX1l3IEHb83DD8QFjAEegQIDRAD&url=https%3A%2F%2Fem.rutgers.edu%2Fncp%2Fsearch%2FProgramDetails.aspx%3Fid%3D438%26src%3Dbrowse&usg=AOvVaw00pCpfq9nOa5DIxHdxxbry

Ms Xu also works as a Student Volunteer at the Rutgers University School of Pharmacy. Her mentor is 'Dr. Dayuan Gao who is a pediatrician and I volunteered at her clinic (as she does not have a laboratory). For the research, due to quarantine, my team of three including me only had access to resources online. (I do have lots of experience with lab techniques from classes such as AP Biology, Honors Chemistry with Lab, Medical Interventions, and Principles of Biomedical Sciences - the last two being Rutgers courses.'

https://pharmacy.rutgers.edu/directory/gao-dayuan/

To quote Rebecca 'I took preliminary physical measurements such as blood pressure, vision, height, and weight; charted HPI and CC; labelled samples and filled forms for LabCorp and Quest Diagnostics; extracted urine samples; observed blood work; trained new volunteers; and cleaned rooms and took out trash.'

Finally not satisfied with all these contributions to the Public Interest, Rebecca Xu worked at St. Joseph's Seniors Home as a Director of Special Projects stating ' I come up with special projects for the residents, and carry through with them. I also interact with and entertain the residents.'

Ms. Mercedes Padilla - Register, MA, SMART Program Administrator at the New Jersey Medical School and Rutgers, The State University of New Jersey, is a Supervisor of Ms. Rebecca Xu. She has authorized the LSINJ to extend, and Rebecca Xu to take the position of Student Observer/Intern on the Board.

For those Board Members of the LSINJ who also work as Faculty Members, Professors and Deans at Universities around the world, Ms. Rebecca Xu's work ethic, drive, interest in Science as well as in the well-being of her community will echo in many familiar ways.

Rebecca has much to contribute to the Life Sciences Institute of New Jersey in both tangible as well as intangible ways. These include bringing the fresh perspectives of an accomplished student, and moreover the first student who will be contributing to the development of the institute.

Detailed Information Link: (To Be Updated)